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Abstract: Despite recent advances in cancer therapy, current treatments, including radiotherapy,
chemotherapy, and immunotherapy, although beneficial, present attendant side effects and long-term
sequelae, usually more or less affecting quality of life of the patients. Indeed, except for most of the
immunotherapeutic agents, the complete lack of selectivity between normal and cancer cells for radio-
and chemotherapy can make them potential antagonists of the host anti-cancer self-defense over
time. Recently, the use of nutraceuticals as natural compounds corroborating anti-cancer standard
therapy is emerging as a promising tool for their relative abundance, bioavailability, safety, low-cost
effectiveness, and immuno-compatibility with the host. In this review, we outlined the anti-cancer
properties of Lactoferrin (Lf), an iron-binding glycoprotein of the innate immune defense. Lf shows
high bioavailability after oral administration, high selectivity toward cancer cells, and a wide range of
molecular targets controlling tumor proliferation, survival, migration, invasion, and metastasization.
Of note, Lf is able to promote or inhibit cell proliferation and migration depending on whether it
acts upon normal or cancerous cells, respectively. Importantly, Lf administration is highly tolerated
and does not present significant adverse effects. Moreover, Lf can prevent development or inhibit
cancer growth by boosting adaptive immune response. Finally, Lf was recently found to be an ideal
carrier for chemotherapeutics, even for the treatment of brain tumors due to its ability to cross the
blood–brain barrier, thus globally appearing as a promising tool for cancer prevention and treatment,
especially in combination therapies.
Keywords: lactoferrin; cancer; lactoferrin bioavailability; tumor proliferation; apoptosis; epithelial to
mesenchymal transition; metastasis; cancer targeting
1. Lactoferrin: A Brief Overview
It’s just over 80 years since the glycoprotein Lactoferrin (Lf) was first discovered in bovine milk [1]
and later purified as an iron-containing red protein from human milk [2]. This glycoprotein is present
in milk from different species such as cow, pig, mouse, horse, rabbit, and dog and its production is
species- and lactation stage-dependent [3,4]. Notably, concentration of Lf in human milk is the highest
among the different species, with the maximum peak in colostrum (6.7 g/L) and lower concentrations
in transitional (3.7 g/L) and mature milk (2.6 g/L) [4]. Despite its name, Lf was subsequently found
to be present also in other biological fluids including saliva, tears, mucus, seminal fluid, bronchial
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secretions, and in secondary granules of neutrophils [5]. Lf is functionally and structurally similar to
serum transferrin with 60% sequence identity [6]. As a matter of fact, this glycoprotein, also known as
lacto-transferrin, is classified as a member of the Transferrin (Tf) family, in addition to melano-, ovo-,
and serum-Tf (sTf) [7]. Transferrins are a superfamily of iron-binding proteins constituted by a single
polypeptide chain of 650–700 residues with a two-fold internal repeat derived from an earlier gene
duplication event, which gives rise to an N-lobe and a C-lobe. The two homologous lobes share about
40% sequence identity and each of them can reversibly bind a ferric ion [8]. Both Lf and sTf have high
affinities for Fe3+ (Kd = 10-20 M, [9]) due to a highly conserved set of ligands for the ferric ion [10,11].
However, Lf and sTf differ in some physicochemical properties, in particular Lf has high iron binding
stability at low pH, whereas sTf releases iron under such conditions [6]. This different feature reflects
distinct functions of the considered proteins: indeed, sTf acts as a cargo for iron transport not only into
cells [12] but also in the blood, a district that it is usually characterized by pH values in a narrow neutral
range (7.2–7.4) [13], while Lf often exerts its role at inflamed and infected sites, where pH can reach
acidic values. Indeed, Lf shares its anti-microbial, antifungal, antiviral, and anti-parasitic activities
with ovo-Tf [14,15], whereas it possesses unique features as an anti-inflammatory, immunomodulatory,
and anti-cancer molecule [16–18]. Moreover, it is emerging as a fundamental regulator of cellular and
systemic iron homeostasis [19,20]. All the activities ascribed to Lf can be dependent or independent of
its iron-binding ability.
The Lf primary structure has been characterized in multiple species [9]. Human Lf (hLf) shows
high similarity with other Lfs isolated from bovine (bLf), horse, and buffalo [21–23]. It is an 80 kDa
single polypeptide chain of 691 amino acids, with the N- (residues 1–333) and C- (residues 345–691)
lobes connected by a three-turn-helix peptide (residues 334–344) (Figure 1) [24]. Ferric ligands are
constituted by two tyrosines (Y92 and Y192 for N-lobe and Y433 and Y526 for the C-lobe), a histidine
(H253 for N-lobe and H595 for C-lobe) and an aspartic acid (D60 for the N-lobe and D395 for the
C-lobe), that, along with two oxygens from a CO32- ion, form a binding site with an octahedral
geometry [9]. Lf is a cationic protein (pI ca. 9), rich in basic amino acids especially in the N-lobe, which
presents two peptide sequences, namely lactoferricin (Lfcin, aa. 1–47 in hLf and 17–41 in bLf) and
lactoferrampin (Lfampin, aa. 269–285 in hLf and 268–284 in bLf), which have been described to possess
their own biological functions (Figure 1) [25,26]. Both peptides can be generated by Lf tryptic digestion
after oral ingestion, thus suggesting their physiological implication in gut homeostasis. Indeed,
Lfcin and Lfampin are endowed with potent anti-microbial [26,27], anti-fungal [28], anti-viral [29],
anti-inflammatory [30], and anti-cancer properties [31]. Most of the functions ascribed to these peptides
are due to their high positive charge, which enables them to interact with negatively charged surface
of both prokaryotic and eukaryotic cells, thus altering the permeability of membranes and, in case of
pathogens or cancer cells, inducing cell lysis and death [31,32].
Depending on its iron content, Lf can assume two opposite conformational states, the open
iron-free form (apo-Lf) and the closed iron-binding form (holo-Lf) [33]. The native form of Lf, produced
and secreted in physiological conditions, has an iron saturation rate between 10% and 20%, thus
leading to the prevalence of apo- and monoferric Lf and a very low content of diferric Lf. On the
other hand, in inflammation and/or infection sites, characterized by high levels of free iron, the
holo-form is mostly present. Interestingly, the iron content influences the physico-chemical properties
of Lf [34]. First of all, holo-Lf is more stable than the unsaturated form, with higher thermal stability
and a significant resistance to proteolytic digestion [34]. Some of the functions exerted by Lf can
also be affected to its iron-binding status, as it is able to scavenge free iron in fluids and inflamed
and/or infected sites, suppressing free radical-mediated damage and decreasing the availability of the
metal to pathogens and cancer cells. In addition, many studies have shown that, depending on the
iron-saturation rate, Lf can exert dissimilar functions by activating specific signaling pathways [35,36].
It is, therefore, of the utmost importance to consider the iron saturation rate when carrying out in vitro
and in vivo experiments.
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highlighted  in  orange  and  the  C‐lobe  in  cyan,  the  connecting  α‐helix  (aa.  334–344  for  both 
glycoproteins) in violet, and the ferric irons are depicted as black spheres. The lactoferricin (aa. 1–47 
in hLf  and  17–41  in bLf)  and  lactoferrampin  (aa.  269–285  in hLf  and  268–284  in bLf)  regions  are 
highlighted  in  blue  and  green,  respectively.  N‐terminal  regions,  able  to  interact  with  different 
glycosaminoglycans on cancer cells, are depicted in red and correspond to the first five amino acids 
(G1RRRR5) for hLf, while in bLf only Asn in position 5 (N5) is shown, as the first four amino acids 
(A1PRK) are absent in the crystal structure. As evident from the top view, the cationic lactoferricin, 
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and  recombinant  human Lf  (rhLf)  contains  two major  glycosylation  sites, Asn  138  and Asn  479 
[37,38], but different N‐glycan patterns [39]. Indeed, rLf expressed in cow has a lower content of sialic 
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(Asn233, 281, 368, 476, and 545) compared to only one in murine Lf (Asn 476) [41]. However, in bLf 
only four sites are invariably glycated (Asn233, Asn368, Asn476, and Asn545) [21], whereas Asn281 
can selectively undergo glycosylation, giving rise in this case to a higher molecular mass bLf (84kDa 
vs. 81kDa) [42]. 
Despite  the  structural  differences  reported  above,  bLf  has  been  classified  as  and  hLf 
bioequivalent  by  virtue  of  high  sequence  homology  and  function  sharing  and,  in  addition,  it  is 
classified  as  a  “generally  recognized  as  safe”  (GRAS)  substance  by  the  USA  Food  and  Drug 
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Figure 1. Side (A,B) and top (C,D) views of the crystal structures of diferric human lactoferrin
(hLf) (A,C) (PDB code = 1B0L) and bovine lactoferrin (bLf) (B,D) (PDB code = 1BLF). The N-lobe is
highlighted in orange and the C-lobe in cyan, the connecting α-helix (aa. 334–344 for both glycoproteins)
in violet, and the ferric irons are depicted as black spheres. The lactoferricin (aa. 1–47 in hLf and 17–41
in bLf) and lactoferrampin (aa. 269–285 in hLf and 268–284 in bLf) regions are highlighted in blue and
green, respectively. N-terminal regions, able to interact with different glycosaminoglycans on cancer
cells, are depicted in red and correspond to the first five amino acids (G1RRRR5) for hLf, while in bLf
only Asn in position 5 (N5) is shown, as the first four amino acids (A1PRK) are absent in the crystal
structure. As evident from the top view, the cationic lactoferricin, lactoferrampin and the N-terminal
region are packed close to each other and constitute a basic domain able to interact with prokaryotic
and eukaryotic cell surface receptors, thus exerting multifaceted activities.
Lf biological function is also influenced by glycosylation, the most common protein
post-translational modification affecting protein folding, immunogenicity, protein solubility, and
resistance to proteolysis. Glycosylation is a species-specific and tissue-specific modification, e.g., hLf
and recombinant human Lf (rhLf) contains two major glycosylation sites, Asn 138 and Asn 479 [37,38],
but different N-glycan patterns [39]. Indeed, rLf expressed in cow has a lower content of sialic acid
and fucose, showing high mannose-, hybrid-, and complex-type structures, while N-glycans from hLf
are comprised entirely of highly branched, highly sialylated, and highly fucosylated complex-type
structures [40]. Bovine, caprine and ovine Lfs present five potential glycosylation sites (Asn233, 281,
368, 476, and 545) compared to only one in murine Lf (Asn 476) [41]. However, in bLf only four sites
are invariably glycated (Asn233, Asn368, Asn476, and Asn545) [21], whereas Asn281 can selectively
undergo glycosylation, giving rise in this case to a higher molecular mass bLf (84kDa vs. 81kDa) [42].
Despite the structural differences reported above, bLf has been classified as and hLf bioequivalent
by virtue of high sequence homology and function sharing and, in addition, it is classified as a “generally
recognized as safe” (GRAS) substance by the USA Food and Drug Administration. Therefore, the
majority of the in vitro [43,44] and in vivo studies [45,46], as well as clinical trials [47,48] have been
conducted by using commercial bLf rather than the highly costing rhLf. Furthermore, bLf is currently
used to supplement food products and cosmetics, to inhibit oxidation due to its iron-binding capacity,
and in infant formulas to improve the immune response in newborn. However, differences in the
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primary source of bLf, and in industrial procedures, influencing bLf integrity and purity, have shown
great impact on the efficacy of commercial bLf preparations, especially in vivo, where bLf bioavailability
can crucially influence the success or the failure of its action.
2. Lactoferrin Bioavailability: Absorption and Body Delivery
Lf bioavailability represents a bizarre biological issue, since mammals are differently exposed to the
action of endogenous Lf depending on age, ranging from its high abundance during infancy, through
breast feeding, to low availability during development and aging. Indeed, excluding Lf ingestion
in homologous or heterologous form from milk, normal diet remains a poor source of exogenous
Lf, also depending on individual habits, while systemic Lf is exclusively guaranteed by neutrophils
degranulation in infection and inflammatory states. In healthy condition, Lf concentration in blood
is rather variable yet always relatively low, varying from 0.02 to 1.52 µg/mL, whereas it increases
during infection, inflammation, excessive intake of iron, or tumor growth [49]. However, most of the
in vitro studies on the multi-functional activities of this protein, including the anti-inflammatory and
anti-cancer ones, showed that higher concentrations need to be used for Lf to be effective, therefore,
exogenous Lf must be administered in vivo to overcome this drawback. Several tests in both animals
and humans have proven its safety and tolerability, even at high dosages. In particular, no adverse
effect was observed in both rats orally administered with bLf at 2 g/kg per 13 days and in humans
with 1.5–9 g of rhLf per 15 days [50,51]. Non-invasive administration routes remain preferable in
humans and among them, although bearing some limitations, oral management represents a safe and
practical approach for Lf supplementation. Beside oral administration [48], several different other
modes have been tested in animal models and humans, including aerosolized [45,46], intranasal [52],
sublingual [53], intravenous [54], intraperitoneal [55], and intravaginal administration [56].
Bioavailability of orally administered Lf changes over development, with higher intestinal
absorption rate in infants and lower absorption during adulthood. This is consistent with the different
physiological roles of Lf during life. In fact, Lf exerts pivotal roles during lactation, both in enhancing
newborn immune defense and promoting milk iron absorption. A pioneer study on intestinal iron
absorption in human infants has shown that human milk helps the metal to be absorbed up to 50%,
while absorption of iron from bovine milk and infant formula remains considerably lower, 5%–20% [57].
In this respect, Lf, which carries most of the iron in milk, is undoubtedly the main actor in increasing
iron bioavailability from human milk [58]. In infants, gastrointestinal absorption of antigenically intact
proteins is much higher due to a freely permeable gut [59]. Studies in piglets have shown that the gut is
easily passed through by various macromolecules, mostly during the first few days post-partum [60,61].
Consistent with this, Lf has been shown to be efficiently transferred from the intestine into systemic
circulation in a newborn [62] as well as in 3–5-month old calves [63], piglets [64], and infants [65]. In
addition, the immature state of the neonatal gastrointestinal system, characterized by a moderately
high pH and low secretion of proteolytic enzymes, has been correlated to the persistence of intact Lf
during gastrointestinal passage [66]. So far, it is widely recognized that, in infants, Lf survives gastric
digestion, thus maintaining the ability to interact with its specific receptor in the small intestine [66].
In contrast, studies on gastrointestinal digestion kinetic of Lf in adults have highlighted that rhLf from
transgenic cows is completely digested [67], whereas about 60% of bLf was found undigested [68].
Therefore, in human adults, bLf appears to be more resistant than hLf against proteolytic degradation,
suggesting that hLf is “designed” to be ingested orally only during infancy. In order to increase
bLf bioavailability, the oral administration should be performed before meals so to avoid its gastric
degradation due to very low pH during digestion.
Once in the intestine, hLf can interact with its receptor and be internalized by enterocytes, then
partially vehiculated into the bloodstream and delivered to tissues. The presence of human Lf receptors
(hLfRs) in the small intestine was proposed for the first time by Cox and colleagues [69]. Upon
incubation of mucosal biopsies from adult human small intestine with 59Fe-labeled hLf, bLf, human
serum transferrin (Tf), and ovo-Tf, they found that Lfs, but not serum or ovo-Tf, were able to deliver
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iron to human duodenal mucosa. By using the same approach, they demonstrated that iron from
human Tf, but not from Lf, was taken up by reticulocytes, suggesting the peculiar role of transferrin
as blood iron shuttle and ruling out the involvement of Tf in iron absorption from the intestinal
mucosa [69]. It is interesting to recall that, among mammals, rat is the only species presenting Tf as the
only iron-cargo protein in milk, ensuring iron absorption in rat intestine [70,71]. Therefore, rat should
be considered a poor model for studying Lf intestinal absorption and tissue delivery, being devoid of Lf
receptors on mucosal cells. In a subsequent study, Ashida and colleagues demonstrated that holo-hLf
was internalized from the apical side but not from the basolateral one in polarized monolayers of
Caco-2 cells, a human cell line of intestinal derivation, whereas holo-hTf was internalized only from
the basolateral one [72].
A number of unsolved questions and controversies emerge from studies on the transepithelial
transport of Lf in adults, which consists in the internalization and subsequent release of the protein in
the lamina propria. Most of in vitro studies, usually performed on polarized monolayers of intestinal
cell lines, have disclosed a major degradation pathway for the internalized hLf [73–75], and a minor
one for its transepithelial transport [76], yet a very recent report showed that intact hLf and its N-lobe
derivative, after cell uptake, were both released back into culture medium [77]. These contradicting
data can be due to the heterogeneous features of the Caco-2 cell line as well as to different culture-related
conditions [78].
On the other hand, in vivo studies on the intestinal transepithelial transport of oral administered
bLf, have reported more robust evidence for the vehiculation of intact bLf into systemic circulation in
adult pigs [79], rats [80], and mice [81], via both the lymphatic pathway and the portal vein [64,79,80].
Compared to a significant amount of relevant studies demonstrating Lf intestinal absorption, only a
few papers have shown evidence of tissue delivery of systemic Lf. Some reports have pointed out
that systemic Lf is rapidly cleared from liver after intravenous injection, both in mice and rats [82,83],
thus excluding the possibility of its effective transfer to tissues. However, Fisher and coworkers
demonstrated that significant levels of the exogenous glycoprotein were recorded in different organs,
such as the liver, gall bladder, kidneys, spleen, and brain, in mice intra-gastrically administered with
bLf, suggesting that circulating bLf is efficiently delivered to the entire body [81].
Mammalian hLfRs have been shown to reproduce the multifunctional activities of hLf, as they are
differentially expressed according to tissue and cell type [66]. In fact, hLf, upon binding to its receptor,
can trigger different intracellular signaling pathways [84] or undergo clathrin-mediated endocytosis
and subsequent nuclear translocation [72], thus enabling Lf to act as a regulator or transregulator of
cellular gene expression [16]. In 1991, Kawakami and Lonnerdal isolated the first human intestinal
receptor from fetal intestinal brush-border membranes [85], while, in 2001, Suzuki and colleagues
cloned and functionally studied it [86]. This receptor is currently known as intelectin-1 (ITLN-1).
ITLN1 is a high affinity Lf receptor (Kd = 10-6 M) able to transduce several Lf-mediated functions,
ranging from facilitation of intestinal iron absorption in infants to strengthening of the immune
system [87–90]. A thorough screening of adult murine tissues revealed that INTL1 is expressed in the
digestive tract (esophagus, stomach, small intestine, and large intestine), nervous system (cerebellum,
hypothalamus, hippocampus, pituitary gland, ganglia, and spinal cord), reproductive system (testes
and ovaries) and other organs, such as the pancreas, renal cortex, lung, heart, and liver [91], thus
suggesting its pivotal role into the redistribution of circulating Lf into the body. So far, in humans,
INTL1 was found on the intestinal brush-border, Paneth and goblet cells [66] as well as on biliary
epithelium [92].
Besides INTL1, low density lipoprotein (LDL) receptor-related protein (LRP) plays a pivotal role
in Lf metabolism and signaling. It is mainly known to be involved in hepatocyte uptake of lipoproteins
containing triglycerides and cholesterol through an endocytotic-mediated pathway. However, it
was also shown to take part in several cellular processes, including cell migration, survival, motility,
and differentiation, playing a role in different pathologies such as thrombosis, fibrinolysis, and
atheroscleosis [93]. LRP is ubiquitously expressed in hepatocytes, neurons, smooth muscle cells,
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fibroblasts, and cholangiocytes [92], and it has been shown to be involved in the hepatic removal
of bLf from plasma [94]. Moreover, bLf translocation across the blood-brain barrier (BBB) was also
demonstrated to be LRP-mediated [95].
Concerning other hLfRs, CD14 was exclusively found on monocytes, asialoglycoprotein receptor
(ASGPR) in liver and nucleolin in lymphocytes [66,96]. Interestingly, hLf ability to enter into the
nucleus [97] is possibly mediated by both ITLN1 and surface nucleolin [98,99]. Therefore, due to the
receptor specificity, hLf can exert multiple and differential functions depending on the cell system it
acts upon.
Concerning bLf, its interaction with hLfRs was first described by Shin et al. [100], and its nuclear
localization in human enterocytes in a further study [101], thus strengthening and partially explaining
how bLf could act as a potent bioequivalent of the human homologue.
Overall, despite most of Lf-mediated molecular mechanisms still being under investigation,
signal transduction following Lfs-hLfRs interaction and the ability of Lf to enter into the nucleus
likely represent the main mechanisms through which Lfs exert its pleiotropic functions, including
anti-inflammatory, immunomodulatory, and anti-cancer roles.
3. Lactoferrin and Cancer
Over the 1970s and 1980s, several different functions have been ascribed to Lf, including
antibacterial, antimicrobial, and immunomodulatory abilities, yet it was only in 1994 that Bezault
and coworkers presented convincing data about the anti-cancer activity of hLf in murine models of
fibrosarcoma and melanoma [102]. In particular, intraperitoneal administration of hLf was found
to inhibit both solid tumor growth and lung metastasis independently of the iron-saturation rate
of the protein. In the same report Lf anti-cancer ability was correlated to the activation of Natural
Killer (NK) cells [102]. At odds with these findings, a negative correlation between endogenous hLf
expression and cancer incidence was demonstrated in different cancer cell lines, all showing a marked
down-regulation of hLf transcript [103–105]. Lf gene silencing in cancer cells was found to be related to
different molecular mechanisms, including promoter and gene hyper-methylation or direct alteration
of the gene sequence [106–108]. Interestingly, Zhang and colleagues showed that the restoration of
hLf gene expression through the use of a methyltransferase inhibitor impaired cancer cell growth and
metastasis in a model of oral squamous cell carcinoma [108]. Generally, hLf and bLf have been shown
to exert anti-cancer activity for both tumor prevention and treatment [18,109]. The Lf preventive
effect has been demonstrated in several animal models bearing different types of tumors, including
lung, tongue, esophagus, liver, and colorectal [110–113], whereas Lf treatment was found efficient in
inhibiting growth, metastasis, and tumor-associated angiogenesis [18,114,115], as well as in boosting
chemotherapy [116,117].
In humans, Lf application in clinical trials for cancer prevention is almost impracticable for
most of the tumors, however, investigations on its potential use for the treatment of specific type of
pre-cancerous lesions, in order to prevent their transformation in highly tumorigenic cells, have been
carried out [118,119]. In particular, in 2002–2006, Tsuda research group investigated the inhibitory
effects of orally administered bLf on the growth of pre-cancerous adenomatous colorectal polyps in a
clinical trial carried out on 104 participants, with ages ranging from 40 to 75, at the National Cancer
Center Hospital, Tokyo, Japan. The participants were divided into three groups, acquiring 0 (placebo
group), 1.5, or 3 g of bLf daily over one year [118]. The results showed that, whereas the lower dose
did not exert any significant effect, the higher dose was able to hinder the growth of colorectal polyps,
in patients 63 years old or younger, when compared to the placebo group. Interestingly, serum hLf
levels in patients acquiring 3 g of bLf were found to be significantly increased already after 3 months of
treatment, consistent with an increase in neutrophils activity [118]. In 2014, the same group enriched
the study by presenting data on the correlation between immune parameters and polyps size [119].
Trial participants with regressing polyps presented: i) increased NK cell activity and higher numbers
of CD4+ cells in the polyps, consistent with the activation of the adaptive immunity and ii) decreased
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numbers of polymorphonuclear neutrophils and increased numbers of S100A8+ cells in the polyps,
consistent with the down-regulation of inflammatory stimuli [119]. Overall, although the molecular
mechanisms remain unveiled, the Tokyo clinical trial represents a pivotal upshot showing the efficiency
of oral bLf administration in counteracting cancer development in humans.
Besides general clinical aspects, several molecular mechanisms underlying Lf anti-cancer ability
have been unveiled, including the modulation of cell cycle, promotion of apoptosis, hindering of
migration and invasiveness, as well as immunomodulation. Except for the indirect immunomodulatory
pathway, the other mechanisms require the direct recognition of and selection between cancerous
and normal cells by Lf, possibly involving a primary interaction with peculiar cancer cell surface
receptors or a secondary one via the regulation of differential intracellular networks. To date, only
few evidences have been reported for the primary recognition between Lf and cancer cell surface
receptors [120–122]. In this respect, most of cancerous cells have a high content of proteoglycans,
glycosaminoglycans (GAGs, mainly heparan and chondroitin sulfates), as well as of sialic acids, all
these molecules being well-known interactors for Lfs [120,123,124]. This crude recognition could be
at the base of Lf anti-cancer specificity and selectivity. The N-terminal portion of hLf, containing a
unique cluster of four consecutive arginine residues (G1RRRR5), was demonstrated to be essential for
hLf interaction with GAGs on the human colon carcinoma cell line HT29-18-C1 as well as on Jurkat
human lymphoblastic T-cells [123,125]. Interestingly, N-terminal region of bLf, which shows a different
consensus sequence (A1PRKN5), is able to interact with cell membrane-associated GAGs similarly
to hLf [125]. Moreover, Riedl and colleagues have shown that phosphatidylserine, a cytoplasmic
membrane component largely represented on tumor cells, is a crucial target for the specific anti-cancer
activity of human Lfcin (Lfcin-H) derivatives [126]. This primary selective interaction via cell surface
receptors can explain the most archaic function ascribed to Lf, i.e., its cytotoxic activity. Indeed,
especially at high concentrations, both hLf and bLf and even more their derived peptides have been
found to promote cytotoxicity and cell death for both prokaryotic and eukaryotic pathogens [127–129],
as well as for cancer cells [130–133]. This activity has been mostly associated to the cationic charge of Lfs
which can promote electrostatic interactions with negative charged cell surface receptors. Concerning
Lf derived cationic peptides, their low specific mass weight enables them to enter and destabilize cell
membrane thus easily inducing a lytic process [31]. As a matter of fact, many current treatments for
cancer rely on antimicrobial peptides which display high specificity for targeting cancer cells and low
toxicity for normal cells [134].
Overall, due to similar cell selectiveness, hLf, bLf, and their derived peptides have been tested
and recognized to exert pivotal role in cancer prevention and treatment. Insights on the most current
advances in Lf anti-cancer field are reviewed below according to the specific effects and mechanisms.
3.1. Lactoferrin Anti-Cancer Activity: Modulation of Cell Cycle
The mammalian cell cycle is normally tightly controlled, mainly by hormones and growth factors,
and its dysregulation can lead to tumor development. Cyclins, ciclin-dependent kinases (CdKs) and
their antagonists, the CdK inhibitors, are key players in the regulation of cell cycle progression. In
mammals, the active complex in G1 comprises cyclin A, cyclin D–CdK4/6, and cyclin E–CdK2. The
interaction between cyclin D and CdK4/6 leads to the phosphorylation of retinoblastoma (Rb) protein,
which, in mid-to-late G1 phase, promotes the release of different transcription factors bound by Rb,
resulting in the activation of gene transcription and DNA synthesis. The assembly and activation of
cyclin E and CdK2 follows, regulating further steps required for DNA synthesis in S phase [135]. This
process is tightly regulated by CdK inhibitors, which hamper the binding between the cyclin and its
specific CdK. Among them, p21, p27, and p57, belonging to the CIP/KIP family, inhibit the kinase
activities of cyclin D-CdK4, cyclin D-CdK6, cyclin E-CdK2, and cyclin A-CdK2.
Despite most of the chemotherapeutic agents are addressed to arrest cell cycle and to induce
cytotoxicity in cancer cells, they usually do not discriminate between normal and cancer cells, thus
leading to a series of adverse and dramatic effects on patients. Conversely, Lf has been described to act
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as a selective agent with regard to cancer and normal cells. As a matter of fact, Lf was found to mainly
act as a positive regulator of proliferation in normal cells [136,137], while exerting a predominant
inhibitory effect versus transformed and cancer cells [18], thus highlighting once again its innate
selectivity and differential potential.
Lf is able to act as a growth factor, by enhancing, in a dose-dependent manner, DNA synthesis
and cell growth of normal cells, including neonatal rat hepatocytes [138], human endometrial stroma
cells [139], primary rat and human osteoblast cells [140,141], and human embryonic kidney cells [141].
Recent studies have unveiled the molecular mechanisms involved in Lf pro-proliferative effects in
MC3T3-E1 osteoblast cell line in vitro [136,137]. In particular, the native forms of both bLf and hLf
have been shown to shorten the cell cycle, in a dose-dependent manner, by upregulating the mRNA
expression of Proliferating Cell Nuclear Antigen (PCNA), thus globally enhancing the number of cells
found in S and G2/M phases [136]. Similarly, bLf significantly enhances cell growth via phosphorylation
of both extracellular-signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK),
while preventing the activation of c-Jun N-amino-terminal kinase (JNK) [137].
Concerning cancer cells, hLf was found to arrest cell growth, in G1 to S transition phase of the cell
cycle, in a model of breast cancer, the MDA-MB-231 cells [142]. At the molecular level, hLf induced
a significant decrease in the protein levels and activity of both Cdk2 and Cdk4, responsible for the
activation of cyclin D and cyclin E, respectively, which, in turn, play a key role in the transition from G1
to S phase. Moreover, CdK inhibitor p21 was found increased in a p53-independent mechanism [142].
This hLf effect was also reported in four models of head and neck cancer cells, which resulted
arrested in G1 to S transition upon hLf treatment [143]. Lf anti-proliferative effect was associated to
the increase of CdK inhibitor p27 protein accompanied by the suppression of cyclin E. The increased
levels of p27 were related to decreased phosphorylation of Akt, which determines a reduction in p27
phosphorylation and subsequent increased resistance of the protein to proteasomal degradation [143].
In the study by Zhang et al. [144], the inhibitory effects of bLf on the growth of four breast
cancer cell lines (T-47D, MDA-MB-231, Hs578T, and MCF-7) but not on the normal breast cell line
MCF-10-2A, were reported, thus confirming the selectivity of Lf. Interestingly, only the full-length
glycoprotein, especially in its iron-saturated form, but not its derived peptides, was active in this
inhibitory effect. The Authors showed that bLf-mediated arrest of cell cycle was associated to the
increase of phospho-AMP activated serine/threonine protein kinase (AMPKα) and decreased levels of
both phosphorylated and total forms of mTOR, the nutrient/energy sensor kinase involved in several
cell pathways including cell survival. Therefore, the downregulation of total and phospho-mTOR
following the activation of AMPKα signaling was proposed as the molecular mechanism responsible
for bLf-mediated cell cycle arrest [144].
In line with these studies, Chea et al. [145] showed that bLf was able to induce cell cycle arrest
also in a model of oral squamous cell carcinoma by increasing levels of both phospho-p53 and CdK
inhibitor p21 and decreasing the expression of cyclin D1, a regulator protein required for progression
through G1 phase of cell cycle. Importantly, bLf neither down-regulated phospho-p53 and cyclin D1
nor up-regulated p21 levels in RT7 cells, a normal human oral keratinocytes line [145].
Lastly, also bovine Lfcin (Lfcin-B) was described to be able to block cell cycle in human colon
cancer CaCo-2 cells [146]. Indeed, Lfcin-B was able to induce a slight but significant prolongation of S
phase when compared to untreated cells by down-regulating the level of cyclin E1 [146].
3.2. Lactoferrin Anti-Cancer Activity: Induction of Apoptosis
The term ‘apoptosis’ describes the biological mechanism by which a cell actively pursues a
path toward its death upon specific stimuli. As a highly selective process, apoptosis is pivotal in
both physiological and pathological conditions. Principal mechanisms described for the induction
of apoptotic process include the extrinsic and the intrinsic pathways. The extrinsic one, also named
‘the death receptor pathway’, requires a ligand to bind to a death receptor. Among them, the type 1
tumor necrosis factor (TNF) receptor (TNFR1) and the related protein Fas, as well as their ligands, TNF
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and Fas ligand (FasL) respectively, are the most studied [147]. Along with the binding of the death
ligand to the death receptor, an adaptor protein intervenes forming a protein complex known as the
death-inducing signaling complex (DISC) [148]. DISC then initiates the assembly and activation of
pro-caspase 8, which in turn activates caspase-3 or cleaves Bid, a family member of Bcl-2, leading to
the formation of the apoptosome and to final activation of caspase-9 [147]. In the intrinsic pathway,
internal stimuli, such as DNA damage, severe oxidative stress and hypoxia, are responsible for the
induction of apoptosis. It involves the release of pro-apoptotic molecules such as cytochrome-c from
the mitochondria to the cytoplasm, with the downstream activation of proteins belonging to the
Bcl-2 family [149]. These latter group of regulatory proteins include both pro-apoptotic (e.g., Bax,
Bak, Bad, Bcl-Xs, Bid, Bik, Bim, and Hrk) and the anti-apoptotic (e.g., Bcl-2, Bcl-XL, Bcl-W, Bfl-1, and
Mcl-1) proteins, whose ratio directly determines the cell fate [150]. Furthermore, all these regulators of
apoptosis are modulated by several upstream intracellular pathways, including Akt, ERK1/2, and JNK.
In cancer, the succession of genetic changes accumulating in transforming cells results, besides
higher proliferation rate and migration/invasion features, in the cell ability to evade death-inducing
signaling. Therefore, reduced apoptosis or cell resistance play a pivotal role in the carcinogenesis.
In general, cancer cells escape apoptosis by disrupting the balance between pro-apoptotic and
anti-apoptotic proteins, reducing caspase activity or affecting death receptor signaling. In this scenario,
new drugs or treatment strategies that can rebalance the proper apoptotic response for cancer cells can
potentially function as chemotherapy.
Among its multi-faceted activities, Lf has also been described to be a potent activator of apoptosis
in many different type of cancers [18,151]. HLf-induced apoptosis in Jurkat leukemia T cells has been
described to occur in a dose-dependent manner via the activation of JNK and caspase 9 and 3 which in
turn resulted in increased levels of Bcl-2 phosphorylation [152]. By contrast, upon treatment with a
JNK inhibitor, hLf challenging no longer induced any apoptotic process in the same cell line [152]. A
deeper analysis of the Lf-induced Bcl-2-dependent apoptotic signaling showed that hLf reduces the
formation of the Rb/E2F1 complex by inducing the phosphorylation of Rb, thus promoting the release
of E2F1 transcription factor, a downstream regulator for cell proliferation and apoptosis via activation
of its target genes [153].
By injecting an adenovirus expressing the hLf cDNA into the tumor site in mice bearing EMT6
breast cancer, Wang and coworkers demonstrated that hLf could significantly reduce tumor growth.
At the molecular level, hLf was found to induce the apoptotic process by decreasing the anti-apoptotic
Bcl-2 and increasing the pro-apoptotic Bax and caspase 3 expressions [154]. Moreover, rhLf produced in
the yeast Pichia pastoris has been shown to induce apoptosis through plasma membrane blebbing, cell
shrinkage, and chromatin condensation, as well as the disruption of F-actin cytoskeleton organization
in the human breast cancer cell line MDA-MB-231 [155].
Moreover, bLf was described to induce apoptosis in stomach cancer cell line SGC-7901
by down-regulating Akt intracellular signaling [156]. In particular, bLf treatment induced the
dephosphorylation of Akt in Thr308 and Ser473, thus blocking downstream apoptotic regulators [156].
BLf was also demonstrated to induce apoptotic extrinsic pathway by up-regulating Fas signaling
in the colon mucosa of azoxymethane-treated rats [157]. In particular, upon bLf treatment Fas protein,
but not TNF-R1vexpression, was up-regulated with respect to the vehicle group, along with an increase
in both caspase-8 and caspase-3 levels. Furthermore, immunohistochemistry revealed Fas-positive
cells and apoptotic cells especially within the proximal colon region. Notably, the incidence of tumors
inversely correlated with the areas positive to Fas and apoptosis [157]. In another study, the same
group showed that, altogether with the induction of Fas, also two pro-apoptotic members of the Blc-2
family, Bid and Bax, resulted increased in tumor sites in rat fed with bLf [158].
In a recent paper, Jiang and Lonnerdal described bLf and Lfcin-B, the latter in both linear and cyclic
forms, as potent pro-apoptotic agents against the colorectal cancer cell line HT-29, by inducing different
intracellular pathways [131]. In particular, transcriptome analysis and immunoblotting allowed to
reveal that levels of several intracellular mediators involved in cell cycle arrest and apoptosis were
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increased by treatment with either linear or cyclic Lfcin-B, suggesting that the glycoprotein and Lfcin-B
can exert their anti-cancer activity by triggering different pathways [131]. It is relevant to note that no
cytotoxic and pro-apoptotic effects were recorded on normal human intestinal epithelial cells, once
again confirming the high selectivity of Lf and its derivate peptides.
BLf, both in its apo- and holo forms, was found to inhibit expression of survivin, a 16 kDa
protein overexpressed in several cancer cells [159]. Survivin is able to bind to pro-apoptotic molecules,
including caspases, thus inducing a blockade of apoptotic process [160]. The study by Gibbon and
colleagues reported that both apo- and holo-bLf significantly induced apoptosis in two breast cancer
cell lines, MDA-MB-231 and MCF-7, by decreasing Bcl-2 and pro-caspase-3 expressions, along with a
significant reduction in survivin levels. Importantly, no cytotoxic and pro-apoptotic affect was detected
in breast normal MCF-10-2A cell line [159]. Moreover, the authors underlined the great potentiality of
bLf as inhibitor of survivin since, to date, no survivin inhibitors have passed clinical trials due to their
high toxicity [161].
Recently, the vacuolar H+-ATPase (V-H+-ATPase) was described as a potential target for bLf
in highly metastatic breast cancer cell lines [121,122]. BLf was found to induce apoptosis, along
with a significant decrease in V-H+-ATPase-mediated extracellular acidification rate, in two highly
metastatic breast cancer cell lines, Hs 578T and MDA-MB-231, displaying a prominent localization of
V-H+-ATPase at the plasma membrane, but not in the lowly metastatic T-47D or in the non-tumorigenic
MCF-10-2A cell lines [121]. By a similar approach, bLf was described to selectively act as pro-apoptotic
agent on highly metastatic prostate PC-3 and osteosarcoma MG-63 cell lines, both displaying aberrant
plasma membrane localization of V-H+-ATPase [122]. Again, non-tumorigenic BJ-5ta cell line did not
show sensitivity to bLf treatment. Overall, these studies suggest a common mechanism of action of bLf
against highly metastatic cancer cells exhibiting plasmalemmal V-H+-ATPase, a promising perspective
for its application in the treatment of these cancers.
Finally, Lfcin-B was also described to be involved in the induction of apoptosis [162–164]. Lfcin-B
was found to promote reactive oxygen species (ROS)-dependent induction of apoptotic process in a
human leukemic cell line [162], whereas its nine amino acids variant was demonstrated to activate
apoptosis by up-regulating caspases 3 and 9 via ROS induction in a human ovarian cancer cell
SK-OV-3up [164]. Moreover, pepsin-digested-Lf peptides exerted pro-apoptotic effect in a human
oral squamous cell carcinoma cell line by promoting the cleavage of caspase-3 and poly (ADP-ribose)
polymerase (PARP) as well as by inducing the phosphorylation of ERK1/2 and JNK [165].
Lfcin-B was also shown to significantly inhibit proliferation of non-small cell lung cancer NCI-H460
(H460) cells in vitro by promoting apoptosis through the stimulation of caspase-3 and caspase-9 and
by preventing survivin expression [166]. Moreover, vascular endothelial growth factor (VEGF) was
down-regulated at both transcriptional and translational level along with an increase of intracellular
ROS production by inhibition of antioxidant enzymes. Of note, upon Lfcin-B treatment tumor growth
in the H460-bearing mice model was also prevented [166].
3.3. Lactoferrin Anti-Cancer Activity: Inhibition of Cell Migration, Invasion, and Metastasis
Beside increased proliferation rate and resistance to apoptosis, cancer cells acquire migratory
and invasive phenotypes which allow them to detach from the primary site and enter the circulatory
system, thus metastasizing into distant sites. Cell migratory activity is a fundamental process during
essential physiological processes including morphogenesis, wound healing and tissue regeneration.
This type of migration, known as ‘collective cell migration’, involves large sheets of cells, rather than
single cell, with tight intercellular connections. In adults, wound healing and tissue regeneration are
the predominant processes where physiological cell migration occurs. Indeed, any break in the skin
has to be rapidly repaired to avoid blood loss and the risk of infection. Importantly, inflammatory
mediators are usually involved in wound healing, thus promoting the regeneration of dermal and
epidermal structures. However, chronic inflammatory processes can be detrimental to such healing,
leading to non-repairing wounds.
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Interestingly, bLf was found to directly stimulate the proliferation and migration of fibroblasts,
predominant cells in the dermis responsible for the generation of granulation tissue in wound healing,
and keratinocytes, essential cells for re-epithelialization [167,168]. Moreover, addition of bLf to
differentiating HaCaT human keratinocytes led to increased transepithelial electrical resistance (TER),
a marker of epithelial barrier function as well as to upregulation of two differentiation markers,
involucrin and filaggrin [169]. BLf was also described to promote hyaluronan synthesis in normal
human dermal fibroblasts by increasing hyaluronan synthase 2 [170], suggesting that Lf-stimulated
wound healing could be related to up-regulation of hyaluronan. In corneal epithelial wound healing,
bLf promotes wound closure in human corneal epithelial cells [171].
The rhLf was shown to stimulate re-epithelialization of porcine second-degree burns [172], and
bLf favored healing of corneal alkali wounds in BALB/c mice, associated with down-regulation of
interleukin (IL)-1α and β [173]. Of note, bLf was demonstrated to promote rapid wound healing in
the post-surgical treatment of patients suffering from bisphosphonate-related osteonecrosis of the
jaws [174].
As expected, Lf showed selectivity by efficiently inhibiting migration and/or invasion in different
types of cancer cell models [36,159,175,176]. Despite most of the studies do not detail the molecular
mechanisms at the base of Lf anti-migratory and anti-invasive activities, two recent investigations have
shed some light on bLf ability to revert epithelial-to-mesenchymal transition (EMT) process in both
oral squamous cell carcinoma (OSCC) [176] and glioblastoma [36] cell lines. EMT is recognized as one
of the main processes involved in cancer metastasis, where cells that gain a more invasive phenotype
become able to infiltrate blood vessels as well as surrounding and distant tissues [177]. Different
transcriptional factors play a crucial role, including Signal Transducer and Activator of Transcription
3 (STAT3) [178], Snail, and Twist [179]. Indeed, Snail and Twist, overexpressed in highly metastatic
malignant tumors, repress cell-to-cell adhesion molecules, such as cadherins. On the other hand, such
tumors show high levels of vimentin, a major intermediate filament protein, which has been positively
associated with cancer aggressiveness, progression, and poor outcomes [180].
Chea et al. [176] showed that bLf was efficient in counteracting invasiveness of the OSCC line,
HOC313, by reverting EMT process. At the molecular level, upon binding to LRP1, bLf suppressed Twist
expression by downregulating ERK1/2 phosphorylation, along with an up-expression of E-cadherin
and the decrease of vimentin levels. Additionally, the in vitro results were confirmed also in xenografts
of mice orally administered with bLf, showing less cancer cell infiltration and increased levels of
E-cadherin [176].
In our study, native and holo-bLf were able to partially or completely hinder cell migration in a
human glioblastoma cell line, the GL-15. In particular, depending on its iron saturation rate, bLf was
efficient in down-regulating both vimentin and Snail expression, while inducing a notable increase in
total cadherins’ level. Moreover, IL-6/STAT3 axis, another pivotal pathway associated to glioblastoma
cell migration ability, was found to be strongly inhibited upon bLf treatment, with the holo-form more
efficient than the native counterpart. Interestingly, the differential efficiency was associated to higher
accumulation rates of holo-bLf in both cell cytoplasm and nucleus with respect to the native form [36].
A schematic representation of molecular mechanisms targeted by bLf for EMT reverting is shown in
Figure 2.
Along with anti-migration and anti-invasion effects, Lf was primarily reported to affect cancer
metastasis. As described above, in 1994 Bazault and colleagues reported the first evidence for the
anti-metastatic effect of Lf in rat models [102]. Since then, several studies have reported the Lf
anti-metastatic ability against other types of cancers [87,88,181,182]. In particular, subcutaneous
administration of apo-bLf and Lfcin-B in mice inoculated with two different cancer cell lines, B16-BL6
melanoma and L5178Y-ML25 lymphoma cells, resulted in significant inhibition of liver and spleen
metastasis for L5178Y-ML25 cells and lung metastasis for B16-BL6 cells, as well as of tumor-induced
blood vessel formation [181]. Moreover, apo-bLf was significantly efficient in suppressing the growth
of B16-BL6 cells throughout the whole experimental period (21 days), whereas Lfcin-B had an effect
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only during the first 8 days [181]. Interestingly, neither apo-hLf nor holo-bLf were able to exert the
same functions, suggesting species and iron-saturation specificity for this activity.Biomolecules 2020, 10, x  12  of  26 
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and invasion by re erti epithelial-to-mesenchymal transition (EMT) process in cancer cells.
(A) Mesenchymal phenotype, charact rized by a spindl -like shape, presents high levels of vimentin
and Snail/Twist (S/T), down-regulation of cadherins’ expression and p-STAT3-activation by int rleukin
(IL)-6. All these factors let the cel to ac i e phenotype able to detach from the primary
site and invade surrounding tis ues an l l . (B) Epithelial phenotype upon bLf treatment,
which is able to revert EMT by its multi-tar it . fter LRP1-mediated uptake and nuclear
localization, bLf down-regulates vimenti , Snail nd Twist expression, thus increasing cadherins’ levels.
Moreover, bLf inhibits IL-6-mediated STAT3 activation.
The oral administration of bLf an f i - t /c ice bearing subcutaneous implants of
the highly metastatic colo carcinoma, 26 reduced lung metastatic colony formation [87]. While
Lfcin-B was by itself active in this inhibitory effect, bLf showed a significant activity depending on the
activation of white blood cells towards asialoGM1+ and/or CD8+ phenotypes [87].
Recently, Wei and colleagues demonstrated that Lf deficiency enhanced melanoma metastasizing
to lungs in an Lf KO mouse model by recruiting myeloid derived suppressor cells (MDSCs). Molecular
studies showed that TLR9 signaling, negatively involved in MDSC-mediated cancer metastasis, was
highly repressed and that exogenous Lf administration was able to revert the phenotype by enhancing
TLR9 pathway as well as by inducing MDSCs differentiation and apoptosis [182].
3.4. Lactoferrin Anti-Cancer Activity: Immunomodulation
To date, it is well established that the tumor microenvironment, mainly composed and coordinated
by inflammatory cells, is a crucial component in the tumor progression or inhibition. The inflammatory
participants to cancer microenvironment principally involve leukocytes, including dendritic cells,
neutrophils, and macrophages, as well as lymphocytes, all able to secrete various inflammatory
mediators, such as cytokines, cytotoxic molecules, including ROS and soluble mediators of cell killing,
such as TNF-α and interferons (IFNs) [183]. The fine interplay between cancer and immune cells can
decide the tumor fate. Several studies have highlighted the pro-cancerogenic role of tumor-infiltrated
leuko ytes through release of som cytokines, such as IL-6 and IL-1β, f u d to be increase in
different ca cer models [184,185]. On he other hand, some subclasses of leukocytes, such a NK
cells and cytotoxic T cells, display potent ant tumor activity [185]. Therefore, the immune response
can ex rt both tumorigenic and anti-tumorigenic activities depending on he balance of innate or
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adaptive components and on the subtype of cancer it is connected to. In general, a well-orchestrated
acquired immune response has to be considered as anti-tumorigenic, whereas chronic inflammation
induced by unbalanced innate or acquired immune response is likely pro-tumorigenic. In this scenario,
molecules able to boost cytotoxic immune components as well as to shut down pro-tumorigenic
inflammatory mediators could be considered potentially good candidates as adjuvant to standard
anti-cancer therapies. In this regard, Lf has proven to potentiate adaptive immune response as well
as to act as a potent anti-inflammatory agent [17,102,186]. Even if the molecular mechanism is still
under debate, the findings that both hLf and bLf are able to enter inside host nucleus [97,101] and to
bind human DNA have shed some light on the possible mechanism by which the glycoprotein can
modulate gene expression, thus exerting its anti-inflammatory activity [17].
HLf was reported to significantly increase NK cells-mediated cytotoxicity against breast and
colon cancer cell lines [120]. Interestingly, hLf pre-treatment of NK cells or target cells enhances NK
cytotoxicity activity and target cell sensitivity to lysis, respectively. Consistently, in a murine model of
cervical carcinoma expressing hLf, Shi and Li demonstrated that the reduction of tumor growth in the
hLf-treated group was associated to an induction of NK cells activity and an increase of CD4+ and
CD8+ T lymphocytes in peripheral blood. Moreover, hLf-treated mice showed an increase of serum
INF-γ, IL-2, and TNF-α, along with a down-regulation of serum IL-4 and cancer tissue VEGF [187].
In in vitro and in vivo models of head and neck squamous cell carcinoma, rhLf was demonstrated
to induce a dose-dependent growth inhibitory effect by modulating inflammatory and immune
response [188]. The in vitro rhLf-mediated inhibition of cancer proliferation was associated to
up-regulation of NF-kβ signaling as well as to the down-regulation of pro-inflammatory and
pro-metastatic cytokines, including IL-8, IL-6, granulocyte macrophage colony-stimulating factor and
TNF-α. Moreover, in tumor-bearing mice the oral administration of rhLf resulted in a 20-fold increase
of lymphocytes and 75% tumor growth inhibition when compared with vehicle group. Of note, in
mice depleted of CD3+ cells all rhLf treatment was no longer efficient [188].
The oral administration of bLf was described to have a potent anti-carcinogenic activity by
increasing the expression of mucosal IL-18 mRNA in the small intestine of mice [189]. The same
effect, though at different extent, was promoted by the bLf pepsin hydrolysate and Lfcin-B, both
showing a positive influence on IL-18 mRNA expression in the murine small intestine and organ
culture, respectively. Moreover, both bLf and Lfcin-B, in addition to IL-18 activation, were able to
induce a significant up-regulation in caspase-1 activity in peritoneal macrophages, which is directly
involved in the cleavage of pre-mature to mature form of IL-18 protein [186]. Importantly, this
bLf-mediated activation of IL-18 by caspase-1 was found to be dependent on IFN-γ expression by
peritoneal macrophages. As a matter of fact, IFN-γ KO mice were insensitive to bLf oral administration
resulting in unchanged levels of active caspase-1 and mature IL-18. On the other hand, bLf was
still efficient in inhibiting tumor growth in IFN-γ KO mice by activating IFN-α/IL-7 pathway, thus
strengthening the concept that bLf can act as a multi-targeting agent [189].
BLf was reported to inhibit tumor growth in in vitro experiments on a human lung cancer cell
line, A549, as well as in a murine model of lung cancer overexpressing VEGF. Results showed that bLf
treatment reduced VEGF expression in a dose dependent manner, along with a significant reduction of
global cytokine levels, including the pro-inflammatory TNF-α and IL-6 and the anti-inflammatory IL-4
and IL-10 [190]. Additionally, bLf hindered the proliferation, migration, and bone resorption in an
in vitro model of osteosarcoma by attenuating inflammatory processes through the reduction of IL-1β,
IL-6, RANKL, and phospho-NF-kB [191].
Other than the direct modulation of immune response, Lf strategically acts as a potent
anti-inflammatory agent by scavenging ROS, pro-oxidant agents able to both promote DNA damage
and induce/sustain inflammatory disorders, drastically contributing to cancer development. Lf is
able to maintain the physiological balance of ROS levels by either direct binding of free iron, one of
the principal actors involved in ROS production, and regulation of key antioxidant enzymes, thus
globally protecting host from ROS-mediated cell and tissue damages [192]. In this respect, a recent
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study by Mohammed and colleagues have shown that bLf significantly down-regulated the activity
of liver antioxidant enzymes, namely catalase, glutathione peroxidase, and superoxide dismutase,
along with an increase of the concentration of hepatic reduced glutathione, in a murine model of
diethylnitrosamine-induced hepatocarcinogenesis. Accordingly, bLf treatment promoted the decrease
of serum inflammatory markers and significant amelioration in hepatic histological structures [193].
Finally, bLf has been recently proven to protect against iron disorders by modulating immune
response and down-regulating pro-inflammatory cytokines, such as IL-6, in both in vitro [20,194,195]
and in vivo [46] models as well as in clinical trials [48].
3.5. Lactoferrin as a Cargo for Cancer Targeting
In cancer treatment and therapy, different chemical and biological compounds have been tested in
order to increase specificity for tumor cells, without affecting the quality of life of patients. Indeed,
although all tested molecules are endowed with great anti-cancer potential, most of them lack selectivity,
resulting in high cytotoxicity for non-cancer tissues [196]. Hence, specific targeting is becoming an
imperative feature of new compounds in cancer treatments. In this regard, the development of
engineered nanoparticles (NPs), able to act as a specific carrier, is greatly improving the possibility to
specifically deliver drugs. NPs-mediated cancer targeting is ensured by passive and active processes
which can drive NPs efficient localization in the tumor microenvironment and promote their uptake by
cancer cells, respectively. The specific cell uptake is usually guaranteed by the presence of ligands able
to interact with surface membrane receptors overexpressed on target cells. The use of nanocarriers
presents several advantages other than selectivity, including long-term systemic longevity and easy
permeation into cellular membranes. Moreover, nanoparticles-mediated targeting has been proven to
decrease multidrug resistance [197,198]. To date, several ligands have been tested for efficient targeting,
such as organic molecules (e.g., folic acid), antibodies or their fragments, peptides and whole proteins,
including Lf [199].
The simple conjugation of apo- or holo-bLf with Doxorubicin (Dox) was demonstrated to improve
internalization and nuclear retention of Dox into prostate cancer cells, along with a four-fold increase
of Dox-mediated cytotoxicity [200]. Moreover, the complex, but not Dox alone, was efficient in
overcoming multi-drug resistance in an advanced drug resistant cancer cell line. Finally, mice orally
administered with holo-bLf-Dox conjugates showed better survival rates, a marked reduction in tumor
growth and Dox-mediated general toxicity, neurotoxicity and cardiotoxicity, as well as an increase in
serum levels of TNF-α, IFN-γ, CCL4, and CCL17 [200].
The use of Lf-loaded liposomes as anti-cancer drug carrier has also been tested [201,202]. In
particular, bLf-containing polyethylene glycol (PEG)-modified liposomes have been employed in
the targeting of Dox in in vitro and in vivo models of hepatocarcinoma, showing a relevant effect
in improving Dox cellular uptake, which was associated to the presence of asialoglycoprotein
receptors on cancer cell membrane, and to a significant inhibition of tumor growth in mice bearing
HepG2 xenografts compared to mice injected intravenously with the sole Dox-loaded PEGylated
liposomes [201]. Moreover, the intravenous injection of Dox-loaded holo-bLf-liposomes in a murine
model of breast cancer resulted, along with a high accumulation of the nanocomposites in the tumor
site, in tumor suppression and in a higher induction, when compared to mice treated with the sole
Dox-loaded liposomes, of hydrogen peroxide conversion to oxygen, due to the release of ferric ions
following holo-bLf degradation [202]. Similarly, bLf-containing micelles were used for the efficient
targeting of both rapamycin and wogonin to treat breast cancer cells [203]. In general, bLf-micelles
showed good serum stability and blood compatibility. Additionally, they were found to increase
cytotoxicity of rapamycin and wogonin in terms of tumor inhibition in in vitro and in vivo models as a
result of enhanced active targeting [203].
Concerning NPs, different anti-cancer approaches based on Lf-mediated targeting have been
reported [54,204,205]. In particular, Lf was employed as carrier for NPs loaded with anti-cancer
drugs or DNA encoding for anti-cancer effectors. 5-Fluorouracil (5-FU), entrapped in bLf-NPs with
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great efficiency and high storage stability, showed enhanced receptor-mediated uptake, prolonged
intracellular retention and higher cytotoxicity in a melanoma cell line, when compared to free 5-FU [204].
Moreover, bLf and Lfcin-B-bearing dendriplexes containing DNA encoding for TNF-α were applied
in the treatment of mice implanted with both melanoma and carcinoma cells [54]. The intravenous
injection of dendriplexes resulted in the specific expression of TNF-α in tumor tissue with very low
levels of non-specific gene expression in the liver. In one month, the suppression of 60% of carcinoma
tumors and up to 50% of melanoma tumors was observed, with no side effects for animals [54]. Similarly,
the same group demonstrated that the system was highly safe and selective in the suppression of
prostate cancer cells in mice [205].
Importantly, Lf was found efficient in the specific targeting of central nervous system (CNS) by
overcoming blood–brain barrier (BBB) [206–209]. As a matter of fact, one of the most critical limitation
for the treatment of CNS pathologies, including cancer, is represented by BBB which restricts the
delivery of therapeutic agents to the brain. The use of Lf as carrier for CNS treatment is due to the high
expression of LRP1 on cells constituting BBB and even more on glioma cells, the most recurrent type of
cancer in the brain [66,210]. Overall, studies employing Lf-bearing NPs co-loaded with different type
of chemotherapeutics in the treatment of glioblastoma reported a good safety profile, an enhanced
permeation of BBB and efficient drug delivery to glioma cells [206–209].
Taking all these evidences together, it is clear that the use of Lf as a cargo molecule for cancer
therapy is sustained by several advantages: i) high stability and resistance to proteolysis which makes
it suitable for NPs preparation and long-term storage; ii) null or low antigenicity when intravenously
infused; iii) great selectivity for cancer cells due to the overexpression of its target receptors on their
plasma membrane; iv) anti-cancer properties which can markedly improve chemotherapy efficiency;
and v) proven safety even at high dosage.
4. Conclusions
None of the current cancer treatments, including radiotherapy, chemotherapy, immunotherapy,
and surgery, although beneficial, represent a full ideal approach, as all more or less affect the quality of
life of the patients. Recently, the use of nutraceuticals as natural compounds corroborating standard
therapy is emerging as a promising tool for their relative abundance, bioavailability, safety, low-cost
effectiveness, and immuno-compatibility with the host. Moreover, the oral route makes them very
easy to be administered and well tolerated. However, to date, most of nutraceuticals applied in cancer
prevention and treatment have shown limited effectiveness and even, in some cases, antagonist activity
against standard therapies. In this context, a molecule able to both prevent and treat cancer as well as
to boost conventional clinical approaches has to be considered a powerful weapon to unsheathe.
As emerging from the data presented in this review, Lactoferrin, and especially its bovine milk
derivative form, is potentially a strong candidate for anti-cancer alternative treatment with the same
advantages but almost null side effects characterizing standard therapies. Indeed, our feeling is that Lf
will find productive applications in synergy with more conventional therapies, most likely allowing
these latters to be administered at lower, more sustainable doses. As a matter of fact, Lf shows high
bioavailability after oral administration, high selectivity toward cancer cells, no significant side effect
and a wide range of molecular targets controlling tumor proliferation, survival, migration, invasion,
and metastasization. Of note, Lf, according to the system it acts upon, is able to trigger differential
outcomes. Indeed, Lf exerts positive or negative effects on cell cycle progression and cell migration
towards normal and cancer cells, respectively. Moreover, Lf can prevent development or inhibit cancer
growth by boosting adaptive immune response. The ability of Lf to cross the blood–brain barrier
makes it a powerful tool to treat brain tumors. Lastly, Lf was recently found to be an ideal carrier for
chemotherapeutics, thus globally appearing as a promising tool for cancer prevention and treatment,
especially in combination therapies.
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